An animal model for chemotherapy-associated @entity1560 and its prevention by the oral administration of fatty acid XXXX conjugate.

@entity901 @entity2600 @entity1560 @entity19 @entity1674 @entity6741
BACKGROUND: Preoperative chemotherapy for hepatic resection of colorectal liver metastases is associated with the development of chemotherapy-associated @entity1560 (CASH). This increases the risk of perioperative morbidity and mortality. To the authors' knowledge, an animal model for CASH has not been described previously. It has been established that fatty acid @entity6741 conjugates (FABACs) prevent the formation of diet-induced @entity1560 . The current study was designed to establish an animal model of CASH and to use that model to study the effect of FABACs on its occurrence. METHODS: C57BL/6 @entity19 were given different doses of @entity901 and @entity2600 . @entity901 administered once weekly at a dose of 6 mg/kg for a total dose of 24 mg/kg was tolerated best and was associated most consistently with CASH. Thus, that dose was chosen as the induction model for CASH. Subsequently, @entity19 were divided into a control group (no treatment), an @entity901 group, and a CASH-prevention group, which received @entity901 and C20-FABAC at a dose of 150 mg/kg daily. The animals were killed after 28 days. RESULTS: Liver fat content was significantly lower (P < .0001) in the control group (51.63 mg/g) and the prevention group (62.13 mg/g) compared with the @entity901 group (95.35 mg/g). This difference was mainly because of the accumulation of liver @entity1674 in the @entity901 group. CONCLUSIONS: The current results indicated that C57BL/6 @entity19 receiving weekly @entity901 can be used as a model for CASH. Oral FABAC therapy reduced the development of CASH in animals that received @entity901 . To the authors' knowledge, this report is the first description of a model and a potential preventive treatment for CASH.
